This study looks at two ways to treat advanced liver cancer, also called hepatocellular carcinoma (HCC). One way is using immunotherapy (IO), which helps the body's immune system attack cancer. Another way combines IO with a type of radiation called stereotactic body radiation therapy (SBRT), which uses x-rays to target cancer cells. The study wants to find out if adding SBRT helps patients live longer compared to using IO alone. Patients are placed in two groups: one gets IO treatments like atezolizumab, bevacizumab, tremelimumab, and nivolumab; the other gets the same IO treatments plus SBRT. Radiation is given over a few days to target the liver tumors precisely.

• The study lasts for up to 5 years, with regular check-ups every few months.
• Participants get either just IO or IO with SBRT, based on their group.
• Check with your doctor if you can join, as it requires a specific type of liver cancer and other health conditions.

Before joining, patients need a confirmed liver cancer diagnosis, be 18 or older, and not pregnant. They should also have good liver function and must not have had certain prior treatments. Health insurance or other payment coverage for treatments is required.